An AI Agent Platform Purpose-Built for Pharmaceutical CDMOs
Transforming pharmaceutical CDMOs with next-generation AI agents
SINCE 2018
Origin: A Cross-Domain Team Driving Innovation
therapiAI was founded in 2018 by experts across biotechnology, artificial intelligence, pharmaceutical manufacturing, quality engineering, and intellectual property.
We recognized that although the pharmaceutical industry generates extensive data, fragmented systems, complex workflows, and strict regulatory requirements have hindered true digital transformation.
This is why we focus on the most demanding segment of the industry — CDMO biomanufacturing — to build AI Agents that truly understand real production environments, deploy quickly, and can be trusted in GMP-regulated settings
Biotechnology
Artificial Intelligence
Pharmaceutical
Engineering
Quality Engineering
Intellectual Property
therapiAI Platform Features
Comprehensive AI Agent Platform Solutions for Intelligent Pharmaceutical Operations
therapiAI provides an AI Agent platform purpose-built for pharmaceutical CDMOs, enabling enterprise-wide upgrades across business development, R&D, production, and operational decision-making.
BioFusion Analytics AI Agent
Transforms imaging and process data into actionable early-stage predictive insights through multimodal AI.
Accelerate cell line selection and yield prediction to shorten development timelines and boost decision confidence.
GMP AI Agent
Streamlines complex GMP compliance documentation workflows.
Empower QA, RA, and engineers to achieve faster, consistent compliance with automated interpretation and comparison.
Transcriber AI Agent
Converts every meeting, interview, and discussion into structured knowledge within seconds.
Automate speech-to-text and summarization to streamline information extraction and accelerate cross-department collaboration.
Tutor AI Agent
An intelligent training assistant that supports Q&A, assessment generation, and training record creation around the clock.
Optimize training workflows to ensure consistent quality, faster knowledge transfer, and effortless audit preparation.
News & Insights
News
[CEO Perspective] Sober Reflections Amidst the AI Investment Frenzy: How CDMOs Can Navigate the J-Curve and Achieve Long-Term Structural Profits
The Investment Dilemma: The “Must-Play” Game of the Era. AI has emerged as the defining strategic priority and a primary target for capital allocation across industries. From pharmaceuticals to retail, companies are aggressively deploying Generative AI and automation at a velocity that outstrips any technological shift of the past two decades. Yet, despite the massive
[CEO’s Vision] AI Reshaping the ADC CDMO Business Model: Opportunities, Challenges, and the Future of Specialized Models
Antibody-Drug Conjugates (ADCs) are among the most promising precision therapies today. By combining the high targeting capability of monoclonal antibodies with the potent cytotoxicity of small-molecule drugs, they have become a new focal point in the R&D of cancer and immune diseases. For pharmaceutical companies, ADCs signify an expansion of clinical pipelines; for Contract Development
[CEO Insights] A New Paradigm for ADC R&D: From DoE to AI Agents, Accelerating Process Manufacturability and DAR Control
ADC Opportunities and Challenges: High Technical Barriers are the Cornerstone of Long-Term CDMO Advantage. For pharmaceutical CDMOs, ADCs present immense commercial opportunities. On one hand, the rapid expansion of global clinical pipelines is driving outsourcing demand. On the other hand, the high cross-disciplinary technical barriers give CDMOs that master DAR (Drug-to-Antibody Ratio) control and process
《therapiAI Launches World’s First GMP AI Agent in Partnership with Leading Biopharmaceutical Manufacturers》
[Taipei, Feb 23] — TherapiAI, a leader in AI-driven pharmaceuticals, announced today the launch of the world’s first GMP AI Agent specifically engineered for Pharmaceutical CDMOs. The agent features advanced RAG (Retrieval-Augmented Generation) capabilities for global regulations, including FDA and ICH guidelines, enabling enterprises to navigate shifting regulatory landscapes in real-time.Currently, TherapiAI has initiated strategic
Success Cases
Client Stories
FAQ
Frequently Asked Questions
Yes. The therapiAI Agent Platform is purpose-built for pharmaceutical companies, CDMOs, and CMC workflows.
Through AI-driven collaboration, it streamlines R&D processes, shortens development cycles, reduces trial-and-error experiments, accelerates GMP document generation, and enhances business decision-making.
It supports departments across R&D, PD, QA, and BD, enabling end-to-end intelligent transformation.
The platform provides AI-powered image analysis, prediction, and inference to identify high-potential cell lines, significantly reducing experimental time and manpower cost while improving R&D efficiency and production competitiveness.
Optimax integrates image-recognition models with machine learning to predict high-productivity cell lines at early stages, shortening the screening process and reducing manual culturing workload.
Yes. therapiAI supports standard API integration with LIMS, QMS, ERP, and other enterprise systems.
Most projects can begin fine-tuning with as few as 500 data entries, without retraining the entire AI engine, and customized onboarding plans are provided.
Yes. Projects can start with small datasets (around 500 entries).
If data is limited, therapiAI specialists can provide tailored implementation plans to ensure successful deployment.
Optimax visualizes key variables and parameter interactions, helping researchers analyze results faster, enhance cross-team communication, and improve overall research efficiency.
Yes. The platform uses a “non-retained, non-centralized” data architecture.
All computation takes place within the client’s private cloud, ensuring data security and regulatory compliance.
Yes. The therapiAI Agent Platform incorporates continuous-learning mechanisms, enabling models to improve prediction accuracy over time as new data is added.
Our main clients are medium to large pharmaceutical companies and CDMOs with stable production lines and regulatory requirements.
Flexible collaboration plans are available for companies of different scales.
therapiAI adopts a subscription-based model, supporting both long-term enterprise deployment and flexible onboarding for new clients.
For details, please contact our team.
[email protected]
Clients report shorter R&D cycles, reduced trial-and-error costs, faster document review, improved BD performance, and higher delivery efficiency.
Yes. therapiAI provides API and on-premise integration services, connecting with systems such as LIMS, ERP, and GMP document management platforms to ensure secure and efficient workflows.
AI delivers core value in CDMO operations—optimizing processes, improving scheduling, predicting quality outcomes, automating documentation, reducing costs, and driving intelligent manufacturing transformation.
Unlike companies focusing on drug discovery or clinical analytics (e.g., BenchSci, Recursion), therapiAI focuses on CDMO process management and compliance documentation, offering AI Agents that directly integrate with production environments and deliver tangible, measurable value.
Because CDMOs operate in the most complex, data-intensive, and regulation-heavy environments.
therapiAI aims to build AI Agents that truly understand CDMO workflows and can be trusted and deployed quickly—helping define future standards for intelligent pharmaceutical manufacturing.
For its strong focus on compliance, trustworthiness, and measurable outcomes.
therapiAI simultaneously delivers value at both the production-line and regulatory levels,
supported by multiple proven success cases.
[email protected]
therapiAI is an AI company headquartered in Taipei, Taiwan, specializing in AI Agents for the pharmaceutical CDMO sector.
Its solutions enhance efficiency and compliance across R&D and manufacturing workflows.
Michael Han.
therapiAI was founded by Michael Han, Alicja Lee, and Polly Lin.
The team includes AI engineers, biomedical scientists, regulatory specialists, and industry advisors.
The company’s predecessor, Akousist, was founded in 2018.
It rebranded to therapiAI in 2024 to focus on accelerating CMC/CDMO workflows with AI.
“To make pharmaceutical manufacturing smarter, more efficient, and more trustworthy.”
Our mission is to rebuild CMC workflows through AI and establish the foundation for intelligent manufacturing.
therapiAI is headquartered in Taipei, Taiwan, serving pharmaceutical and CDMO clients across the Asia-Pacific region.